KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndromes
Interventions
DEVICE

CliniMacs TCR alpha-beta-Biotin system

Graft ex vivo depleted of T cell receptor (TCR) αβ+CD3+/CD19+ cells

Trial Locations (11)

10595

New York Medical Center, Valhalla

19104

Children's Hospital of Philadelphia, Philadelphia

37232

Vanderbilt University - Monroe Carell Jr. Children's Hospital, Nashville

53226

Medical College of Wisconsin, Milwaukee

60611

Lurie Children's Hospital, Chicago

84112

University of Utah, Primary Children's Hospital, Salt Lake City

90027

Children's Hospital Los Angeles, Los Angeles

92123

Rady Children's Hospital, San Diego

94143

University of California, San Francisco, San Francisco

94305

Stanford University Medical Center, Palo Alto

94609

Children's Hospital Oakland, Oakland

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University of California, San Francisco

OTHER

collaborator

Children's Hospital of Philadelphia

OTHER

collaborator

Medical College of Wisconsin

OTHER

collaborator

Ann & Robert H Lurie Children's Hospital of Chicago

OTHER

collaborator

New York Medical College

OTHER

collaborator

UCSF Benioff Children's Hospital Oakland

OTHER

collaborator

Vanderbilt University

OTHER

collaborator

Rady Children's Hospital, San Diego

OTHER

lead

Michael Pulsipher

OTHER

NCT02646839 - KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children | Biotech Hunter | Biotech Hunter